Updates in Multiple Myeloma
Cilta-cel Boosts Survival in Lenalidomide-Refractory Multiple Myeloma

Teclistamab Extends Survival Vs SOC in Refractory Multiple Myeloma Trial

Optimizing Cellular Therapy Use Across All Stages of Multiple Myeloma

FDA Clears IND Application for KLN-1010 in R/R Multiple Myeloma

Subcutaneous Isatuximab Regimens Show Efficacy in R/R Multiple Myeloma
 

Teclistamab Extends Survival Vs SOC in Refractory Multiple Myeloma Trial

Nogapendekin Alfa Combo Earns Saudi FDA Accelerated Approval in NMIBC Type
  NEW VIDEO
How to elevate multidisciplinary care in pancreatic cancer?
Videos Trending

FDA Issues New CRL for Tabelecleucel in Epstein Barr Virus–Positive PTLD

Atezolizumab Combo Does Not Significantly Boost Survival in Ovarian Cancer

Videos
  Trending
 

Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma - Expert Perspectives on AQUILA Phase 3 Trial and FDA Approval
Explore the evolving treatment strategies for high-risk smoldering multiple myeloma, emphasizing early intervention and recent clinical advancements.

Featured Video

Evolving Treatment Approaches in EGFR- Mutated NSCLC: First-Line Therapies and AE Management
Dr. Husain, MD, discusses how new clinical data from ELCC 2025, including findings from MARIPOSA and FLAURA-2, are redefining first-line treatment and sequencing strategies for EGFR-mutant NSCLC to improve long-term outcomes and CNS control.

Featured Video  

Chemoimmunotherapy Before Radiation Improves Survival in Stage III NSCLC

Investigators Launch Phase 3 Trial of Calderasib Combo in Advanced NSCLC

Videos Trending

 

FACE-OFF: Low-Risk MDS ASH 2025
Face-Off by CancerNetwork® is not your typical oncology discussion—it’s a high-energy, head-to-head showdown where top cancer institutions debate the latest breakthroughs in a debate. With a mix of friendly competition, expert insights, and a touch of humor, Face-Off makes complex data exciting and engaging. Designed for fellows, junior oncologists, and key stakeholders, this lively program turns learning into an interactive experience that’s as entertaining as it is educational!

Featured Video
FACE-OFF: Low-Risk MDS ASH 2025
Clinical Implications of COMMANDS Trial

Frontline Tafasitamab Combo Improves PFS in Newly Diagnosed DLBCL

Intravenous Olvi-Vec Yields Responses in NSCLC and SCLC Following Progression

Videos
Re-Engaging Patients in Medical Oncology With Scientific Discourse Trending